2024
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Y, Li F, Du L. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses. Journal Of Nanobiotechnology 2024, 22: 304. PMID: 38822339, PMCID: PMC11140877, DOI: 10.1186/s12951-024-02573-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19HumansMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSingle-Domain AntibodiesSpike Glycoprotein, CoronavirusVirus InternalizationConceptsReceptor-binding domainPathogenic human CoVsHeavy-chain antibodiesSARS-CoV-2Development of nanobiotechnologiesPathogenic human coronavirusesSingle-domain antibodiesSARS-CoV-2 variantsS proteinViral entry processHuman CoVsViral spikeReemerging pathogensEvaluation of therapeutic agentsSARS-CoVVirus pathogenesisVariable domainsNanobodiesViral structuresPandemic potentialMERS-CoVPathogenic coronavirusesViral entryBinding affinityHuman coronaviruses
2023
Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53
Lee J, Menasche B, Mavrikaki M, Uyemura M, Hong S, Kozlova N, Wei J, Alfajaro M, Filler R, Müller A, Saxena T, Posey R, Cheung P, Muranen T, Heng Y, Paulo J, Wilen C, Slack F. Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53. Cell Reports 2023, 42: 113478. PMID: 37991919, PMCID: PMC10785701, DOI: 10.1016/j.celrep.2023.113478.Peer-Reviewed Original ResearchMeSH KeywordsCellular SenescenceChromatinCOVID-19Giant CellsHumansMiddle East Respiratory Syndrome CoronavirusProteomicsSARS-CoV-2Tumor Suppressor Protein p53ConceptsChromatin accessibilityProteomic compositionCellular senescenceTP53 stabilizationSARS-CoV-2 spikeCell-cell fusionPathogenic coronavirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsSenescence-associated inflammationSARS-CoV-2 infectionMiddle East respiratory syndromeAccessibility stateInflammatory cytokine releaseSevere respiratory infectionsSARS-CoV-2 variantsSignificant public health threatCoronavirus disease 2019SARS-CoV-2Public health threatBreakthrough infectionsRespiratory infectionsCytokine releaseSenescenceDisease 2019Respiratory syndromeStructural basis for translation inhibition by MERS-CoV Nsp1 reveals a conserved mechanism for betacoronaviruses
Devarkar S, Vetick M, Balaji S, Lomakin I, Yang L, Jin D, Gilbert W, Chen S, Xiong Y. Structural basis for translation inhibition by MERS-CoV Nsp1 reveals a conserved mechanism for betacoronaviruses. Cell Reports 2023, 42: 113156. PMID: 37733586, DOI: 10.1016/j.celrep.2023.113156.Peer-Reviewed Original ResearchMeSH KeywordsHumansMiddle East Respiratory Syndrome CoronavirusRNA, MessengerSARS-CoV-2Severe acute respiratory syndrome-related coronavirusViral Nonstructural ProteinsConceptsMERS-CoV nsp1Translation inhibitionRibosomal subunitΒ-CoVsModest sequence conservationMRNA entry channelEssential pathogenicity factorHost gene expressionHuman 40S ribosomal subunitSARS-CoV-2 nsp1Cryogenic electron microscopySequence conservationNon-structural protein 1Terminal domainPathogenicity factorsStructural basisGene expressionDevelopment of antiviralsNSP1Entry channelProtein 1Potential therapeutic targetSubunitsExtensive interactionsTherapeutic targetThe KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression
Wei J, Alfajaro M, Cai W, Graziano V, Strine M, Filler R, Biering S, Sarnik S, Patel S, Menasche B, Compton S, Konermann S, Hsu P, Orchard R, Yan Q, Wilen C. The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. PLOS Pathogens 2023, 19: e1011351. PMID: 37410700, PMCID: PMC10325096, DOI: 10.1371/journal.ppat.1011351.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2AnimalsCOVID-19Dipeptidyl Peptidase 4Histone DemethylasesHumansMiceMiddle East Respiratory Syndrome CoronavirusReceptors, VirusSARS-CoV-2ConceptsMouse hepatitis virusReceptor expressionTherapeutic targetMERS-CoVMajor SARS-CoV-2 variantsPrimary human airwaySARS-CoV-2 variantsNovel therapeutic targetViral receptor expressionSARS-CoV-2Histone methyltransferase KMT2DIntestinal epithelial cellsCoronavirus SusceptibilityDiverse coronavirusesHistone demethylase KDM6ADPP4 expressionCoronavirus receptorsHost determinantsHepatitis virusHuman airwaysSARS-CoVSmall molecule inhibitionViral entryPotential drug targetsViral receptorsDYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine M, Cai W, Wei J, Alfajaro M, Filler R, Biering S, Sarnik S, Chow R, Patil A, Cervantes K, Collings C, DeWeirdt P, Hanna R, Schofield K, Hulme C, Konermann S, Doench J, Hsu P, Kadoch C, Yan Q, Wilen C. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. PLOS Biology 2023, 21: e3002097. PMID: 37310920, PMCID: PMC10263356, DOI: 10.1371/journal.pbio.3002097.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2AnimalsCOVID-19Dipeptidyl Peptidase 4HumansMiddle East Respiratory Syndrome CoronavirusSARS-CoV-2Severe acute respiratory syndrome-related coronavirusVirus InternalizationConceptsGenome-wide CRISPR/Cas9 screenCRISPR/Cas9 screenPathogenic human coronavirusesKinase-independent mannerRegulated kinase 1AProviral host factorNovel drug targetsMultiple cell typesDNA accessibilityHost factorsKinase functionHuman coronavirusesHost genesDistal enhancerNovel regulatorCas9 screenKinase 1AGene expressionNeuronal developmentDYRK1ADrug targetsDiverse coronavirusesProviral activityCell typesSevere acute respiratory syndrome coronavirus 2
2022
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng L, Fang Z, Renauer PA, McNamara A, Park JJ, Lin Q, Zhou X, Dong MB, Zhu B, Zhao H, Wilen CB, Chen S. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Reports 2022, 40: 111160. PMID: 35921835, PMCID: PMC9294034, DOI: 10.1016/j.celrep.2022.111160.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansLiposomesMiddle East Respiratory Syndrome CoronavirusmRNA VaccinesNanoparticlesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccines, SyntheticViral VaccinesConceptsAntibody responseCoronavirus speciesSequential vaccinationSARS-CoVAntigen-specific antibody responsesSARS-CoV-2 DeltaAdaptive immune cellsEffective immune responsePotent antibody responsesCOVID-19 vaccineSARS-CoV-2MRNA vaccine candidatesActivated B cellsSingle-cell RNA sequencing profilesRNA sequencing profilesSimultaneous vaccinationAntibody immunityVaccination scheduleImmune profileImmune cellsImmune responseVaccine candidatesMERS-CoV.Animal modelsB cells
2021
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, Ruddle NH, Galvani AP, Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. The Lancet Microbe 2021, 2: e666-e675. PMID: 34632431, PMCID: PMC8486316, DOI: 10.1016/s2666-5247(21)00219-6.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCoronavirus 229E, HumanCoronavirus NL63, HumanCoronavirus OC43, HumanCOVID-19Cross ReactionsHumansMiddle East Respiratory Syndrome CoronavirusPandemicsPhylogenyReinfectionSARS-CoV-2Spike Glycoprotein, CoronavirusConceptsDurability of immunitySARS-CoV-2Human-infecting coronavirusesProbability of reinfectionAntibody levelsMERS-CoVSARS-CoVLong-term immune responsePeak antibody responsePublic health decision makingCOVID-19 pandemic continuesEndemic conditionsCOVID-19 morbidityPublic health measuresVirus SARS-CoVHealth decision makingOptical density levelsDevastating COVID-19 pandemicAntibody declineLikely reinfectionAntibody responseEndemic coronavirusesHCoV-NL63Immune responseHuman coronaviruses
2020
mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
Karam BS, Morris RS, Bramante CT, Puskarich M, Zolfaghari EJ, Lotfi‐Emran S, Ingraham NE, Charles A, Odde DJ, Tignanelli CJ. mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses. Journal Of Medical Virology 2020, 93: 1843-1846. PMID: 33314219, PMCID: PMC8159020, DOI: 10.1002/jmv.26728.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsCOVID-19COVID-19 Drug TreatmentHumansMiddle East Respiratory Syndrome CoronavirusRNA VirusesSARS-CoV-2Signal TransductionTOR Serine-Threonine KinasesVirus ReplicationConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus 2 infectionReview of efficacyCoronavirus disease 2019Modulation of mTORSARS-CoV-2RNA virusesDisease 2019Recent evidence pointsMTOR inhibitorsViral infectionMTOR inhibitionMTOR pathwayMammalian targetRapamycin (mTOR) pathwayNumerous RNA virusesVirus growthCOVID-19MTOR resultsInfectionCurrent literatureHighlight evidenceEvidence pointsIntroduction: A New Coronavirus Emerges, This Time Causing a Pandemic
DiMaio D, Enquist L, Dermody T. Introduction: A New Coronavirus Emerges, This Time Causing a Pandemic. Annual Review Of Virology 2020, 7: 1-4. PMID: 32315256, DOI: 10.1146/annurev-vi-07-042020-100001.Peer-Reviewed Original ResearchBetacoronavirusClinical Laboratory TechniquesCommunicable Disease ControlContact TracingCoronavirus InfectionsCOVID-19COVID-19 TestingHumansInfectious Disease Incubation PeriodInformation DisseminationInternational CooperationMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralPsychological DistanceQuarantineSARS-CoV-2Severe Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusSeverity of Illness Index
2018
Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis
Morra M, Van Thanh L, Kamel M, Ghazy A, Altibi A, Dat L, Thy T, Vuong N, Mostafa M, Ahmed S, Elabd S, Fathima S, Le Huy Vu T, Omrani A, Memish Z, Hirayama K, Huy N. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis. Reviews In Medical Virology 2018, 28: e1977. PMID: 29664167, PMCID: PMC7169085, DOI: 10.1002/rmv.1977.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoronavirus InfectionsFemaleHumansInterferonsMaleMiddle East Respiratory Syndrome CoronavirusRisk FactorsTreatment OutcomeConceptsChronic renal diseaseMiddle East respiratory syndromeRenal diseaseSupportive treatmentEfficacy of antiviral drugsAssociated with worse outcomesAntiviral drugsIFN-treated groupLarge-scale prospective randomized studiesProspective randomized studyMonitoring of adverse eventsRisk of mortalitySystematic literature searchOlder age groupsMiddle east respiratory syndrome patientsIFN groupCase fatality rateRandomized studyClinical outcomesAdverse eventsPreexisting comorbiditiesIFN treatmentWorse outcomesSystematic reviewTherapeutic efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply